<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">The tested vaccination strategy elicited potent antibody responses against influenza A group 1 HAs, but low antibody responses against H3, a group 2 HA. A complete pan-influenza virus vaccine will need to consist of a trivalent formulation that contains cHAs for group 2
 <sup>
  <xref ref-type="bibr" rid="CR14">14</xref>
 </sup> and B influenza viruses. Such a multivalent vaccine could induce stalk-reactive antibody responses against all influenza subtypes.
</p>
